Laboratory control of anticoagulant, thrombolytic and antiplatelet therapy

Laffan, Michael; Manning, Richard

doi:10.1016/b978-0-7020-3408-4.00020-5

Cited by 3 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral anticoagulant therapy (OAT) using warfarin is effective and commonly used in the long‐term treatment and prevention of thromboembolic events . Patients on warfarin therapy must, however, undergo regular International Normalised Ratio (INR) testing to ensure that treatment is safe and optimal, as the INR determines the therapeutic dosage . The INR and the use of target INR ranges have simplified and standardized OAT monitoring throughout the world …”

Section: Introductionmentioning

confidence: 99%

Performance evaluation of the microINR^® point‐of‐care INR‐testing system

Joubert

Zyl

Raubenheimer

2017

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Performance evaluation of the microINR^® point‐of‐care INR‐testing system

Joubert

Zyl

Raubenheimer

2017

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Moreover, serum albumin was significantly lower and PT and INR were significantly higher in HCC patients. This could be attributed to the impaired synthetic ability of the liver for albumin and vitamin K, the co-factor of extrinsic coagulation pathway (Laffan, 2006 andJohnson, 2006).…”

Section: Discussion:-mentioning

confidence: 99%

Serum Golgi Protein 73 in Patients With Hepatocellular Carcinoma.

MawgoodGad¹,

Eleraky²,

Abdelrahman³

et al. 2017

IJAR

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. The diagnosis of HCC is mainly based on a combination of abdominal ultrasound and serum alpha fetoprotein (AFP) level. Serum AFP has low sensitivity, serum Golgi protein 73 (sGP73) is a novel and promising biomarker for detection of hepatocellular carcinoma (HCC). However, there are few reports on the predictive values levels of GP73 in diagnosis of HCC. We aimed to evaluate the clinical usefulness of serum GP73 in the diagnosis of HCC. Methods: The study was conducted on 80 patients included 20 patients with chronic hepatitis C (group I), 20 patients with liver cirrhosis (group II divided into two subgroups of equal number compensated and decompensated liver cirrhosis), 40 patients with HCC (group III) in addition to 10 apparently healthy control subjects (group IV). All patients in this study were subjected to full history taking, thorough clinical examination, radiological investigations, routine laboratory investigations and serum AFP in addition to serum GP73 assay by ELISA technique. Results: Assessment of the diagnostic performance of serum GP73 and serum AFP in the present study in diagnosis of HCC revealed that serum GP73 at cutoff of 11.1 ng/mL showed a diagnostic sensitivity of 82.5%, specificity 70%, positive predictive value 78.6%, negative predictive value 75% and the area under the curve (AUC) was 0.8025, Regarding serum AFP at cutoff 320ng/mL showed the diagnostic sensitivity of 79.41%, specificity 60 %, PPV 65.9%%, NPV 75 %, AUC 0.766, This proved the superiority of GP73 estimation over AFP assay in cases of HCC, Conclusion: Serum GP73 had an overall performance better than AFP in detection of HCC in patients with chronic HCV related liver disease so it can be used in diagnosis of HCC.

show abstract

“…The Heparin was used in two different concentrations (low and high; working concentrations of 10 and 100 IU/ml). The testing followed the protocol described in the literature [10].…”

Section: Methodsmentioning

confidence: 99%

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Kumar

Uppal

Ahluwalia

et al. 2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by heparin. HIT occurs due to IgG antibodies directed against heparin-bound platelet factor 4 (PF4). The aim of this study was to evaluate the STic Ò Expert HIT for detection of anti-PF4/heparin antibodies in comparison with ID-PaGIA TM kit. The results were further confirmed by Heparin-induced platelet aggregation test (HIPA). A total of 17 patients with a suspected diagnosis of HIT were enrolled. The 4 T scoring of each case was performed. Testing for HIT was carried out by ID-PaGIA TM , STic Ò Expert HIT, and HIPA. Testing by STic Ò Expert HIT test demonstrated positivity in three cases while testing by ID-PaGIA TM test kit revealed four positive cases. Two of these cases were confirmed as HIT by HIPA. The study suggests that STic Ò Expert HIT an equally effective test, in combination with the 4T scoring system for detecting/excluding the diagnosis of HIT. A large number of cases are needed for validation.

show abstract

Laboratory control of anticoagulant, thrombolytic and antiplatelet therapy

Cited by 3 publications

References 27 publications

Performance evaluation of the microINR^® point‐of‐care INR‐testing system

Performance evaluation of the microINR^® point‐of‐care INR‐testing system

Serum Golgi Protein 73 in Patients With Hepatocellular Carcinoma.

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Contact Info

Product

Resources

About

Laboratory control of anticoagulant, thrombolytic and antiplatelet therapy

Cited by 3 publications

References 27 publications

Performance evaluation of the microINR® point‐of‐care INR‐testing system

Performance evaluation of the microINR® point‐of‐care INR‐testing system

Serum Golgi Protein 73 in Patients With Hepatocellular Carcinoma.

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Contact Info

Product

Resources

About

Performance evaluation of the microINR^® point‐of‐care INR‐testing system

Performance evaluation of the microINR^® point‐of‐care INR‐testing system